Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Ovarian reserve markers and endocrine profile during oral contraception: Is there a link between the degree of ovarian suppression and AMH?

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Low dose HP-hMG in an antagonist protocol for IVF in ovulatory and anovulatory patients with high AMH

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Left-right differences in ovarian volume and antral follicle count in 1423 women of reproductive age

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Hormone therapy modulates ET(A) mRNA expression in the aorta of ovariectomised New Zealand White rabbits

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Serum ferritin level is inversely related to number of previous pregnancy losses in women with recurrent pregnancy loss

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pregnancy outcomes following oocyte donation

    Research output: Contribution to journalReviewpeer-review

View graph of relations

The ovarian reserve markers anti-Müllerian hormone (AMH) and antral follicle count (AFC) are suppressed in varying degree during the use of combined oral contraceptives (COC). Further, long-term use of COC can mask a condition of premature ovarian insufficiency. A desirable clinical tool that could distinguish true low ovarian reserve markers from COC-induced low levels during use of COC is warranted. The aim of this multicenter study including 235 COC users was to assess whether low age-adjusted AMH levels during COC use were linked to concomitant low levels of LH, FSH, estradiol and androgens - as a potential future tool to differentiate between 'false', COC-induced low AMH levels vs. true low AMH. Study population and methods: In total, 235 COC users from the general population aged 19-40 years were included. AMH, AFC and a reproductive hormonal profile were measured during COC intake. Age-adjusted AMH levels (Z-scores) were calculated from a comparison group of 983 non-users of COC. Differences in hormonal profile were tested between women with low versus high age-adjusted AMH-quartiles based on non-parametric Wilcoxon rank sum tests. The outcomes of interest were levels of gonadotropins, estradiol and androgens according to the four the age-adjusted AMH quartiles to find out if women with low age-adjusted AMH levels had a stronger gonadotropin suppression compared with women with higher age-adjusted AMH levels. Mean age of COC users was 30.2 years (SD 3.8), median AMH 14 pmol/l (inter-quartile range (IQR) 8.7-23)), median AFC 16 (IQR 11-25). We found no significant differences across the age-adjusted AMH quartiles in either the levels of gonadotropins, estrogens or androgens, respectively. Thus, the degree of suppression of FSH, LH, androgens and estradiol are unlikely to be a useful tool to differentiate between false low and true low ovarian reserve markers during COC use. Presently, there seems to be no alternative to withdrawal of the COC and to re-test the ovarian reserve after 2-3 months.Trial registration Trial no. NCT02785809 (www.clinicaltrials.gov).

Original languageEnglish
JournalGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
Volume36
Issue number12
Pages (from-to)1090-1095
Number of pages6
ISSN0951-3590
DOIs
Publication statusPublished - Dec 2020

    Research areas

  • AMH, antral follicle count, oral contraceptives, ovarian reserve markers

ID: 59966031